Abstract：
OBJECTIVE: This study aimed to evaluate the efficacy of Ahmed glaucoma valve (AGV) implantation with or without anti-VEGF injections in neovascular glaucoma patients.
METHODS: This single-center retrospective study assessed NVG patients who underwent AGV implantation with or without anti-VEGF injections. Demographic and clinical data, including ocular findings, intraocular pressure (IOP), visual acuity, and glaucoma medication count, were recorded preoperatively and postoperatively at one day, one month, and one year. The study included 35 patients. Group 1 consisted of 23 patients who received anti-VEGF injections before AGV surgery. Group 2, with 12 patients, had no anti-VEGF injections prior to surgery. Successful surgery was defined as IOP values between 6 and 21mmHg. The primary outcome was a 30% or more reduction in IOP.
RESULTS: The groups displayed no significant difference in their demographic or clinical profiles (P>0.05). The visual acuity before and one year after surgery did not differ significantly between the groups. However, IOP values significantly decreased by the end of the one-year follow-up for both groups. No significant differences were found between the groups regarding visual acuity, IOP, or the number of medications during the one-year follow-up (P>0.05). Success rates were 95.7% for Group 1 and 91.7% for Group 2. No significant difference in complications between the groups was observed (P>0.05).
CONCLUSIONS: Anti-VEGF injections prior to AGV implantation did not significantly impact visual acuity, IOP values, or medication count during the one-year follow-up.
METHODS: This single-center retrospective study assessed NVG patients who underwent AGV implantation with or without anti-VEGF injections. Demographic and clinical data, including ocular findings, intraocular pressure (IOP), visual acuity, and glaucoma medication count, were recorded preoperatively and postoperatively at one day, one month, and one year. The study included 35 patients. Group 1 consisted of 23 patients who received anti-VEGF injections before AGV surgery. Group 2, with 12 patients, had no anti-VEGF injections prior to surgery. Successful surgery was defined as IOP values between 6 and 21mmHg. The primary outcome was a 30% or more reduction in IOP.
RESULTS: The groups displayed no significant difference in their demographic or clinical profiles (P>0.05). The visual acuity before and one year after surgery did not differ significantly between the groups. However, IOP values significantly decreased by the end of the one-year follow-up for both groups. No significant differences were found between the groups regarding visual acuity, IOP, or the number of medications during the one-year follow-up (P>0.05). Success rates were 95.7% for Group 1 and 91.7% for Group 2. No significant difference in complications between the groups was observed (P>0.05).
CONCLUSIONS: Anti-VEGF injections prior to AGV implantation did not significantly impact visual acuity, IOP values, or medication count during the one-year follow-up.
摘要：
目的：本研究旨在评估在新生血管性青光眼患者中注射或不注射抗VEGF的Ahmed青光眼阀（AGV）植入的疗效。
方法：这项单中心回顾性研究评估了在注射或不注射抗VEGF的情况下接受AGV植入的NVG患者。人口统计学和临床数据，包括眼部发现，眼内压（IOP），视敏度,和青光眼药物计数，在术前和术后一天记录，一个月,和一年。该研究包括35名患者。第1组包括23名在AGV手术前接受抗VEGF注射的患者。第2组，有12名患者，手术前没有注射抗VEGF。成功的手术定义为IOP值在6和21mmHg之间。主要结果是IOP降低30%或更多。
结果：两组在人口统计学或临床特征上没有显著差异（P>0.05）。手术前和手术后一年的视力在两组之间没有显着差异。然而,在一年的随访结束时，两组的IOP值均显着降低。两组之间在视力方面没有发现显着差异，IOP,或1年随访期间的用药次数(P>0.05)。第1组的成功率为95.7%，第2组的成功率为91.7%。两组并发症比较差异无统计学意义(P>0.05)。
结论：AGV植入前注射抗VEGF并没有显著影响视力，IOP值,或一年随访期间的药物计数。
方法：这项单中心回顾性研究评估了在注射或不注射抗VEGF的情况下接受AGV植入的NVG患者。人口统计学和临床数据，包括眼部发现，眼内压（IOP），视敏度,和青光眼药物计数，在术前和术后一天记录，一个月,和一年。该研究包括35名患者。第1组包括23名在AGV手术前接受抗VEGF注射的患者。第2组，有12名患者，手术前没有注射抗VEGF。成功的手术定义为IOP值在6和21mmHg之间。主要结果是IOP降低30%或更多。
结果：两组在人口统计学或临床特征上没有显著差异（P>0.05）。手术前和手术后一年的视力在两组之间没有显着差异。然而,在一年的随访结束时，两组的IOP值均显着降低。两组之间在视力方面没有发现显着差异，IOP,或1年随访期间的用药次数(P>0.05)。第1组的成功率为95.7%，第2组的成功率为91.7%。两组并发症比较差异无统计学意义(P>0.05)。
结论：AGV植入前注射抗VEGF并没有显著影响视力，IOP值,或一年随访期间的药物计数。
